Taken together, our findings revealed a novel m5C‐independent mechanism for NSUN2 in the malignancy and lapatinib sensitivity of CRC via activation of the CUL4B/ErbB‐STAT3 pathway, which provides a potential therapeutic strategy for patients with CRC. Here, NSUN2 is linked to colorectal carcinoma.